Trials / Approved For Marketing
Approved For MarketingNCT04507503
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Taiho Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.
Detailed description
This is an open-label study to provide expanded access to TAS-120 prior to its commercial availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements who have failed standard therapy or who are unable to tolerate standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-120 | Futibatinib 20mg QD orally on a 28 days cycle |
Timeline
- First posted
- 2020-08-11
- Last updated
- 2026-03-10
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04507503. Inclusion in this directory is not an endorsement.